1 Min Read
LONDON, March 8 (Reuters) - Takeda Pharmaceutical Co Ltd : * Submits marketing authorisation application for vedolizumab in moderately to
severely active ulcerative colitis and crohn's disease in the European union
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.